Sign In
Buy ALLK
$0.329
+0 (+0%)
At Close: Aug 14, 2025
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc. - ALLK
04:10pm, Wednesday, 02'nd Apr 2025
NEW YORK , April 2, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 IS
ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders
10:00am, Wednesday, 02'nd Apr 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Allakos Inc. (NASDAQ: ALLK) to Concentra Biosciences, LLC for $0.33 in cash per share is
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders
08:47am, Wednesday, 02'nd Apr 2025
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Allakos (Nasdaq: ALLK) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
08:00am, Wednesday, 02'nd Apr 2025
SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammat
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
04:02pm, Wednesday, 12'th Mar 2025
SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, infla
Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline
11:30am, Tuesday, 11'th Feb 2025
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to e
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm
05:36pm, Monday, 10'th Feb 2025
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Allakos Inc. (NASDAQ: ALLK) breached their fi
Why Is Allakos Stock Plunging On Monday?
02:05pm, Monday, 27'th Jan 2025
On Monday, Allakos Inc (NASDAQ: ALLK) revealed topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU), a skin disorder.
– AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm
04:15pm, Thursday, 19'th Dec 2024
NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Allakos Inc. (NASDAQ: ALLK) breached their fiduc
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy
01:06pm, Monday, 11'th Nov 2024
Allakos (ALLK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Allakos Runs Up Into A Near-Term Catalyst
05:13am, Thursday, 07'th Nov 2024
Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and chronic spontaneous urticaria. Phase 1 work with intravenous and subcutaneous AK006 demo
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
04:02pm, Wednesday, 06'th Nov 2024
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and pro
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
04:02pm, Thursday, 10'th Oct 2024
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profi
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
04:02pm, Wednesday, 07'th Aug 2024
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and pro
